Allogeneic CAR T has the potential to redefine the future of CAR T. Learn how we are leveraging the unique attributes of investigational AlloCAR T™ products to potentially meet the current and future needs of patients and expand access to treatment. $ALLO #CART #celltherapy #immunotherapy Discover the Allogeneic Advantage: Allogene.com/Home
Allogene Therapeutics’ Post
More Relevant Posts
-
Thank you to all of the providers who support us and trust BENEV Exosomes with their patients! A special shoutout to… 💧Mari De La Roca, LME (@pinskiderm) …for sharing what her experience has been like while using BENEV Exosomes! *Statements made by each provider are of their own experience and not the statements of BENEV Company Inc. #benevskinscience #benevexosomes #exosomes #exosomeregenerativecomplex #exocobio #benev+exocobio #exosometechnology *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.
To view or add a comment, sign in
-
Curious to learn more about our First-in-Human Study of BRB-002? Check out our press release here: https://lnkd.in/euhPue-g #BitterrootBio #BRB002 #FirstinHuman #heartdisease #cardiovascular #drugdevelopment
To view or add a comment, sign in
-
-
Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg http://ow.ly/XzxC105z0m8
To view or add a comment, sign in
-
EXOSOME BEFORE AND AFTER CONTEST Do you have some incredible scalp transformations from using BENEV Exosomes?! From now until 12/31, we’re opening submissions for all BENEV customers to send in their favorite before and afters! Accepted entries that meet the company requirements are eligible for recognition! How To Enter: 1. Post your favorite before and afters of using our Exosomes on the scalp and tag @benevexosomes 2. DM us and fill out our media release forms and upload your images (must be at least 1 month post treatment) 3. Once your images are approved by BENEV’s clinical team and meet all of our requirements, you will receive a message letting you know the next steps! GRAND PRIZE: 1 Box of ERC+ & 1 Box of EXO Balm Contest runs until 12/31 at 5:00 pm PST! You must be a current BENEV Exosomes customer and submit all paperwork required to be eligible. Winner will be announced during the first week of January! #beforeandaftercontest #benevexosomes #exosomeresults Exosome Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
To view or add a comment, sign in
-
-
Are you navigating the complexities of preclinical and clinical trials? Let’s make it simpler together! Meet us at #ASGCT24, booth 2172, where Accelevir and Noble Life Sciences unite to accelerate your path from discovery to delivery. Dive into our full-service offerings in drug, vaccine, and medical device development, enhanced by precise cell and biomarker analytics. 🧬💡 👋 Swing by for a chat, learn more about our exciting collaboration, and enter our iPad raffle! #baltimore #ASGCT24 #cellandgene
To view or add a comment, sign in
-
-
David Smith, Vice President of Development at BioCentriq, emphasized the crucial role of CAR-T cells in the collaboration aimed at tackling manufacturing bottlenecks. CAR-T therapies represent a cutting-edge approach in the realm of personalized medicine, offering promising avenues for treating various diseases, particularly cancer. However, the complexities associated with manufacturing CAR-T cells have posed significant challenges, impacting patient access to these innovative treatments. Through the partnership with Terumo Blood and Cell Technologies, BioCentriq is strategically leveraging advanced platforms to address these hurdles. By optimizing manufacturing processes specifically tailored for CAR-T cells, BioCentriq aims to enhance efficiency, scalability, and reliability in producing these transformative therapies. This collaboration underscores BioCentriq's dedication to advancing CAR-T cell therapy by overcoming manufacturing barriers, ultimately ensuring broader patient access and accelerating the development of next-generation treatments. CAR-TCR Summit Series #immunotherapy #cartcelltherapy #cartcrsummitseries #cancerresearch #cancertreatment #tcrtherapy #innovation
📣 NEW CAR-T Data ‼️ Join David Smith on 2/29 at the CAR-TCR Summit Series Europe for the presentation of the first public CAR-T expansion data from BioCentriq’s collaboration with Terumo Blood and Cell Technologies. The data will demonstrate for the first time publicly, the ability to rapidly produce CAR-T cells using protocols developed by Terumo BCT for its Quantum Flex and Finia® Fill and Finish System platforms in tandem with BioCentriq’s LEAP™ Advanced Therapy Platform. “This collaboration takes aim at the manufacturing bottlenecks that have adversely impacted patient access to CAR-T’s and other advanced therapies,” said David Smith, Ph.D., Vice President of Development at BioCentriq. “It demonstrates how BioCentriq is leveraging Terumo BCT’s platforms to shorten manufacturing timelines and accelerate the development of new therapies.” #CARTCR24 #advancedtherapies #cartcelltherapy #CART #celltherapy #biocentriq #terumo #collaboration #HOPE
To view or add a comment, sign in
-
-
Clinical & Sales Lead | Strong clinical, sales & marketing expertise | Sports Scientist | Driven, resourceful problem-solver in a fast-paced & constantly evolving scale-up environment
One of the hottest topics this year in the #TAVI business, the #SMART trial one-year outcomes were published recently. First findings on this RCT were controversial discussed already Be smart and post your experiences and comments here. It is worth it to exchange experiences, opinions and feedback on this important trial in TAVI when it comes to small annuli and clinical outcomes. #patientsfirst Let‘s also take the opportunity to share experiences during this year’s #EuroPCR in #Paris when it comes to clinical outcome in small annuli comparing intra- vs. supra-annular valve design #smarttrial #europcr #patientsfirst #tavi
LBT at #ACC24! 1-year outcomes of the SMART trial comparing Evolut to SAPIEN valves in small annuli – Explore the data➡️ https://bit.ly/4cM3dgf Sponsored post by Medtronic Cardiac and Vascular
To view or add a comment, sign in
-
We are so excited 😀 to share one of our videos in partnership with @realself that showcase the incredible BENEV portfolio! Shout out to… 💧Richard Jin, MD, PhD (@rjclinicalinstitute) …for sharing why you love using BENEV Exosomes! More stories are to come! *Statements made by each provider are of their own experience and not the statements of BENEV Company Inc. #benevexosomes #exosomeregenerativecomplex #erc #erc+ #benevskinscience #exosome #exosometechnology #exosometreatment *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.
To view or add a comment, sign in
-
First Emirati Scientist in Nanotechnology & its applications in medicine, extensive expertise in medical and clinical research ,made significant contributions to the fields of Nano- medicine & molecular Toxicology .
Nanotherapy from the stages of Nanodrug production and characterisation to clinical exposure and findings
To view or add a comment, sign in
-
Ananda Developments Plc (AQSE:ANA) finance director Jeremy Sturgess-Smith shares promising results from preclinical studies investigating the efficacy of MRX1 in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF). Sturgess-Smith explained that Ananda Developments acquired MRX Medical, the company that owns the MRX1 IP, last year. The company specialises in chronic inflammatory pain conditions and cannabis-based medicinal treatments. The study shows that dosing MRX1 in mice with heart failure and preserved ejection fraction can bring heart and lung weight back to healthy levels and significantly reduce heart failure compounds. Sturgess-Smith emphasised the high unmet medical need in treating heart failure, with limited options beyond diet and exercise. Ananda Developments aims to include MRX1 as part of its treatment portfolio, alongside its existing two Phase II trials investigating... Watch at #Proactive #ProactiveInvestors http://ow.ly/JkEF105ye5S
Ananda Developments announces breakthrough in cardiac study with MRX1
proactiveinvestors.co.uk
To view or add a comment, sign in
Innovative Leadership in Life Sciences & Technology Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies
1moExciting advancements in CAR T therapy, Allogene Therapeutics! Your focus on AlloCAR T™ products to expand patient access is crucial. Looking forward to seeing how these innovations reshape the landscape of immunotherapy. 💫🔬 #CART #celltherapy #immunotherapy